RESUMEN
Objective To investigate the clinical characteristics and prognosis of chronic myeloid leukemia (CML) with the initial symptoms of intracranial space - occupying lesion. Methods The clinical features of a 49 years old CML female patient with the initial symptoms of intracranial occupying lesions in the Affiliated Hospital of Southwest Medical University were analyzed. And the literatures were reviewed and summarized. Results The main clinical manifestations of the patient were headache and blurred vision. Cranial CT showed space occupying lesions in the left frontal lobe. The white blood cell counts(WBC) was 360. 09 × 109/L. Bone marrow smear showed 87. 0％ of granulocyte and 13.5％ of primitive granulocytes,and the patient was diagnosed as CML(accelerated phase). The patient was treated with imatinib 600mg qd,and the disease was controlled. Her intracranial mass was disappeared, and achieved long-term disease-free survival. Imatinib on CML intracranial lesions also had certain curative effect. Conclusion Tyrosine kinase inhibitors(TKIs) should also be individualized for different patients. Dasatinib is the first choice for CML with intracranial occupying lesions. However, this case suggests that imatinib also has clinical efficacy. It may be related to the release of intracranial tumor cells into the peripheral blood or imatinib,and also a small amount of penetration through the blood-brain barrier. In the treatment of CML,appropriate TKIs should be chosen according to the patients'condition.
RESUMEN
Objective To explore the impact of heat shock factor 2 (HSF2) on the development of lung cancer by promoting interleukin (IL)-10 expression.Methods 50 lung cancer tissues and adjacent normal tissues selected from 50 patients,the expression level of mRNA and protein of HSF2 and IL-10 were respectively detected by RT-PCR,Western blot and Immunohistochemistry;To interfere with expression of HSF2 in A549 cells by siRNA,the expression level of IL-10 was detected by Western blot.Results Compared with the adjacent normal tissues,HSF2 of 76％ (38 of 50) cases were up-regulated (P＜0.01),IL-10 of 80％ (40 of 50) eases were up-regulated (P＜0.01),protein level consistent with mRNA level.The up-regulation expression of IL-10 in lung cancer tissues and HSF2 positively correlated (R2 =0.921 6).The expression of IL-10 in A549 cells was weakened through interference with HSF2 by siRNA.Conclusion HSF2 may contribute to the development of lung cancer by facilitating the expression of IL-10.
RESUMEN
Objective To deepen the understanding of curative effect and adverse drug reaction of brentuximab vedotin in the treatment of Hodgkin's lymphoma.Methods One case of newly diagnosed Hodgkin's lymphoma who treated with brentuximab vedotin was collected.The clinical features,laboratory examination,treatment procedure,prognosis were analyzed,and the relevant literature was reviewed.Results The patient was twenty years old,female,found the right neck masses for five days,diagnosed with Hodgkin's lymphoma,mixed cell type,stage Ⅳ group B.Chose the chemotherapy regimen BV + GABVD for 4 courses,the PET-CT indicated CR,then used GABVD 4 courses,now in the stage of clinical observation and followed up.Conclusion BV is a kind of antibody-drug conjugate which targeted on CD30 protein.The FDA approved for the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma.The common adverse reactions are granulocyte,peripheral neuropathy,fatigue,nausea and vomiting.BV can significantly improve the prognosis of CD30 positive Hodgkin's lymphoma,but need to pay attention to the prevention of adverse reactions.
RESUMEN
Objective To explore the clinical feature,diagnosis,therapy and prognosis of primary cardiac lymphoma.Methods One case of primary diffuse large B-cell lymphoma of the heart was studied.The clinical feature,pathogenesis,diagnosis,therapy and prognosis of primary cardiac lymphoma were further investigated through literatures review.Results Patient,female,64 years old,mainly clinical feature with the activities of chest tightness,gas tight,echocardiogram showed right atrial lesions,ECG of sick sinus syndrome.Right atrial tumor excision by pathological examination confirmed the diagnosis of diffuse large B cell lymphoma(DLBCL),treated with R-CHOP (rituximab,cyclophosphamide,vinorelbine,pirarubicin,prednisone) chemotherapy,cardiac pacemaker implantation,the patient had received 3 cycles of chemotherapy currently,and was at the intermission of chemotherapy.Conclusion Primary cardiac lymphoma is extremely rare.Its pathogenesis remained to be unclear.With non-specific clinical manifestations,the diagnosis is mainly confirmed by histopathological and immunohistochemical staining.It is sensitive to chemotherapy generally,but the special location of the tumor leads to poor prognosis.